• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection

by Fred Pennic 10/30/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection

What You Should Know:

– Mayo Clinic announced a collaboration with Vocalis Health to to research and develop new voice-based tools for screening, detecting and monitoring patient health, beginning with a study to identify vocal biomarkers to detect pulmonary hypertension (PH).

– The clinical validation study will utilize Vocalis Health’s proprietary software, which can operate on any connected voice platform (mobile, computer, tablet, etc.) to analyze patients’ health based on voice recordings.

– Following this initial phase, researchers will work to identify vocal biomarkers targeting additional diseases, symptoms and conditions.


Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-based vocal biomarkers for use in healthcare, today announced a collaboration to research and develop new voice-based tools for screening, detecting and monitoring patient health. The collaboration will begin with a study to identify vocal biomarkers for pulmonary hypertension (PH) which could help physicians detect and treat PH in their patients.

Impact of Pulmonary Hypertension

Pulmonary hypertension is a severe condition causing high blood pressure in the lungs, but as the symptoms are similar to other heart and lung conditions, it is often not detected in routine physical exams. While traditional blood tests can sometimes detect pulmonary hypertension, it frequently goes undiagnosed. This strategic collaboration aims to provide an alternative and highly scalable method to check patients for PH, using only a recording of the patient’s voice, to understand their health and the progression of the disease. 

Study Establishes Relationship Between Certain Vocal Biomarkers & Pulmonary Hypertension

In a previous trial with Vocalis Health, the Mayo research team established a relationship between certain vocal characteristics and PH. In this new collaboration, Mayo will conduct a prospective clinical validation study to further develop PH vocal biomarkers. The clinical validation study will utilize Vocalis Health’s proprietary software, which can operate on any connected voice platform (mobile, computer, tablet, etc.) to analyze patients’ health based on voice recordings. Following this initial phase, researchers will work to identify vocal biomarkers targeting additional diseases, symptoms and conditions.

Vocalis Health Background

Vocalis Health is an AI healthtech company pioneering the development of vocal biomarkers – where health-related information is derived from analysis of people’s voice recordings – to screen, detect, monitor and predict health symptoms, conditions and diseases.  Vocalis Health is currently focused on screening users for COVID-19 and on monitoring patients with chronic diseases such as COPD.

“We have seen the clinical benefits of voice analysis for patient screening throughout the COVID-19 pandemic, and this collaboration presents an opportunity for us to continue broadening our research, beginning with pulmonary hypertension,” said Tal Wenderow, CEO of Vocalis Health. “Voice analysis has the potential to help physicians make more informed decisions about their patients in a non-invasive, cost-effective manner. We believe this technology could have important clinical implications for telemedicine and remote patient monitoring in the very near future. We are excited to work with Mayo Clinic and have already started planning clinical trials for additional indications.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Biomarkers, Blood Pressure, Clinical Trials, COPD, Digital Biomarkers, Heart, Hypertension, lung, Mayo Clinic, Patient Monitoring, physicians, remote patient monitoring, telemedicine

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

How to Build Hybrid Care Models Around Remote Patient Monitoring

How to Build Hybrid Care Models Around Remote Patient Monitoring

Most Popular

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

How AI Can Eliminate Surprise Bills, Improve Payment Integrity

AI Can Eliminate Surprise Bills, Improve Payment Integrity

Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing

M&A: Kaiser Acquires Geisinger, Forms Risant Health

5 Executives Weigh in on VBC Impact on Kaiser/Geisinger Deal

Digital Health Executive Hires & Departures

Digital Health Executive Hires & Departures: Ed Marx Departure, Particle Health CEO, Rhapsody CFO, Others

Catalyst by Wellstar Launches $100M Digital Health Venture Fund

Catalyst by Wellstar Launches $100M Digital Health Venture Fund

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |